GlaxoSmithKline: Acute Coronary Syndrome trials
The registry lists 10 Acute Coronary Syndrome studies with GlaxoSmithKline as lead sponsor. 0 are open to participants now and 4 have results posted.
Phase 1 2Phase 2 1Phase 3 4Phase 4 1No phase 2(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Phase 3 Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting With Acute Coronary Syndrome Treated With Losmapimod Compared to Placebo (LATITUDE-TIMI 60)CompletedNCT02145468Phase 3Results posted
- The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 TrialCompletedNCT01000727Phase 3Results posted
- A Study to Evaluate the Safety of 12 Weeks of Dosing With GW856553 and Its Effects on Inflammatory Markers, Infarct Size, and Cardiac Function in Subjects With Myocardial Infarction Without ST-segment ElevationCompletedNCT00910962Phase 2Results posted
- Fondaparinux Trial With Unfractionated Heparin (UFH) During Revascularization in Acute Coronary Syndromes (ACS)CompletedNCT00790907Phase 4Results posted
- A Study to Evaluate the Effect of Losmapimod on Cardiac Conduction as Compared to Placebo and MoxifloxacinCompletedNCT01756495Phase 1
- Phase I Study of GW856553 (Losmapimod)CompletedNCT01648192Phase 1
- SB-480848 in Major Adverse Cardiovascular Events - Integrated Summary of Efficacy and Safety From the STABILITY Trial (LPL100601) and the SOLID-TIMI-52 Trial (SB-480848/033)CompletedNCT01636271
- Fondaparinux EU-RMP (Adherence)CompletedNCT01406301
- Michelangelo - Oasis 5CompletedNCT00139815Phase 3
- OASIS-6 : The Safety and Efficacy of Fondaparinux Versus Control Therapy in Patients With ST Segment Elevation Acute Myocardial InfarctionCompletedNCT00064428Phase 3